Farmer Pierre, Bonnefoi Herve, Becette Veronique, Tubiana-Hulin Michele, Fumoleau Pierre, Larsimont Denis, Macgrogan Gaetan, Bergh Jonas, Cameron David, Goldstein Darlene, Duss Stephan, Nicoulaz Anne-Laure, Brisken Cathrin, Fiche Maryse, Delorenzi Mauro, Iggo Richard
Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Oncogene. 2005 Jul 7;24(29):4660-71. doi: 10.1038/sj.onc.1208561.
Previous microarray studies on breast cancer identified multiple tumour classes, of which the most prominent, named luminal and basal, differ in expression of the oestrogen receptor alpha gene (ER). We report here the identification of a group of breast tumours with increased androgen signalling and a 'molecular apocrine' gene expression profile. Tumour samples from 49 patients with large operable or locally advanced breast cancers were tested on Affymetrix U133A gene expression microarrays. Principal components analysis and hierarchical clustering split the tumours into three groups: basal, luminal and a group we call molecular apocrine. All of the molecular apocrine tumours have strong apocrine features on histological examination (P=0.0002). The molecular apocrine group is androgen receptor (AR) positive and contains all of the ER-negative tumours outside the basal group. Kolmogorov-Smirnov testing indicates that oestrogen signalling is most active in the luminal group, and androgen signalling is most active in the molecular apocrine group. ERBB2 amplification is commoner in the molecular apocrine than the other groups. Genes that best split the three groups were identified by Wilcoxon test. Correlation of the average expression profile of these genes in our data with the expression profile of individual tumours in four published breast cancer studies suggest that molecular apocrine tumours represent 8-14% of tumours in these studies. Our data show that it is possible with microarray data to divide mammary tumour cells into three groups based on steroid receptor activity: luminal (ER+ AR+), basal (ER- AR-) and molecular apocrine (ER- AR+).
先前关于乳腺癌的微阵列研究确定了多个肿瘤类别,其中最突出的是管腔型和基底型,它们在雌激素受体α基因(ER)的表达上存在差异。我们在此报告鉴定出一组具有增强雄激素信号传导和“分子顶泌”基因表达谱的乳腺肿瘤。对49例患有可手术的大肿瘤或局部晚期乳腺癌患者的肿瘤样本进行了Affymetrix U133A基因表达微阵列检测。主成分分析和层次聚类将肿瘤分为三组:基底型、管腔型和我们称为分子顶泌型的一组。所有分子顶泌型肿瘤在组织学检查中均具有强烈的顶泌特征(P = 0.0002)。分子顶泌型组为雄激素受体(AR)阳性,且包含基底型组以外的所有ER阴性肿瘤。柯尔莫哥洛夫-斯米尔诺夫检验表明,雌激素信号传导在管腔型组中最活跃,而雄激素信号传导在分子顶泌型组中最活跃。ERBB2扩增在分子顶泌型中比在其他组中更常见。通过威尔科克森检验确定了最能区分这三组的基因。将我们数据中这些基因的平均表达谱与四项已发表的乳腺癌研究中单个肿瘤的表达谱进行相关性分析,结果表明分子顶泌型肿瘤在这些研究中占肿瘤的8 - 14%。我们的数据表明,利用微阵列数据可以根据类固醇受体活性将乳腺肿瘤细胞分为三组:管腔型(ER + AR +)、基底型(ER - AR -)和分子顶泌型(ER - AR +)。